home / stock / immp / immp news

IMMP News and Press, Immutep Limited From 05/18/23

Stock Information
Company Name: Immutep Limited
Stock Symbol: IMMP
Market: NASDAQ
Website: immutep.com
Menu
IMMP IMMP Quote IMMP Short IMMP News IMMP Articles IMMP Message Board
Get IMMP Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMP - 3 Advanced Penny Stocks Trading Techniques 

2023-05-18 06:00:00 ET Use These Advanced Penny Stocks Techniques to Improve Your Trading Navigating the world of penny stocks comes with its unique set of challenges and rewards. With the right strategies, penny stock trading can potentially be a valuable addition to an investment ...
IMMP - BHC, RIGL and VIRX among mid-day movers

2023-05-17 12:56:05 ET Gainers: Immutep Limited ( IMMP ) +114% . WeTrade Group ( WETG ) +56% . Smart for Life ( SMFL ) +56% . National Western Life Group ( NWLI ) +40% . Bausch Health Companies ( BHC ) +37% . SelectQuote ( ...

IMMP - XBiotech, Impel top healthcare gainers; Intercept, Agile among losers

2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...

IMMP - Immutep jumps 14% on mid-stage data for lead asset in lung cancer

2023-05-17 08:37:59 ET Australian biotech Immutep Limited ( NASDAQ: IMMP ) added ~14% pre-market Wednesday after announcing that lung cancer patients who received its lead candidate efti, in combination with Merck’s ( NYSE: MRK ) Keytruda, recorded a median overal...
IMMP - PACW, CHRS and IMMP are among pre market gainers

2023-05-17 08:29:00 ET Smart for Life ( SMFL ) +37% . Sunrise New Energy  ( EPOW ) +32% FY earnings call release Eightco Holdings  ( OCTO ) +22% Signs Inventory Management Agreement with Prominent Electronics Distributo GD Culture Group&#x...

IMMP - Immutep's Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002 trial Initial median Overall Survival of 25 months in non-small cell lung cancer...

IMMP - Immutep's eftilagimod alpha receives positive FDA feedback for late-stage development in NSCLC

2023-05-16 08:46:48 ET Immutep ( NASDAQ: IMMP ) announced that it received positive feedback from the US Food and Drug Administration regarding the its late-stage clinical development plans for eftilagimod alpha, a soluble LAG-3 protein and MHC Class II agonist, to treat firs...
IMMP - Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, May 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today an...

IMMP - Immutep to Participate in the JMP Securities Life Sciences Conference

Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announ...

IMMP - Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and auto...
Previous 10 Next 10